PERSONAL INFORMATION
Meighan Mary, MPH, B.S.
Assistant Professor – University of Maryland School of Medicine
Dr. Mary is a health systems researcher with over a decade of experience in reproductive, maternal, and neonatal health clinical and implementation research in the U.S, sub-Saharan Africa, SE Asia, and Middle East and North Africa regions. Her research aims to translate clinical evidence into effective maternal and neonatal health programming using mixed methods implementation science, with focus on strengthening linkages between communities and health systems, measurement of quality of care, and maternal and perinatal death surveillance and response (MPDSR).
Dr. Mary is currently co-investigator on the Evidence and Impact for Mothers and Newborns Living in Conflict (EQUAL) research consortium where she co-leads research on MPDSR systems in Eastern Democratic Republic of Congo (DRC) and quality of facility-based maternal and newborn care in DRC and Nigeria. She is also co-investigator on Jhpiego’s Accelerating Measurable Progress and Leveraging Investments for Postpartum Haemorrhage Impact (AMPLI-PPHI) project, co-leading research that aims to assess feasibility and acceptability of a package of PPH interventions (misoprostol, heat-stable carbetocin, and tranexamic acid) in Guinea, DRC, Kenya, and India. Domestically, she is a co-investigator on the Maryland Maternal Health Innovation Program (MDMOM) and serves as a scientific liaison with the NIH Maternal Health Data Innovation and Coordination Hub.
Dr. Mary is currently co-investigator on the Evidence and Impact for Mothers and Newborns Living in Conflict (EQUAL) research consortium where she co-leads research on MPDSR systems in Eastern Democratic Republic of Congo (DRC) and quality of facility-based maternal and newborn care in DRC and Nigeria. She is also co-investigator on Jhpiego’s Accelerating Measurable Progress and Leveraging Investments for Postpartum Haemorrhage Impact (AMPLI-PPHI) project, co-leading research that aims to assess feasibility and acceptability of a package of PPH interventions (misoprostol, heat-stable carbetocin, and tranexamic acid) in Guinea, DRC, Kenya, and India. Domestically, she is a co-investigator on the Maryland Maternal Health Innovation Program (MDMOM) and serves as a scientific liaison with the NIH Maternal Health Data Innovation and Coordination Hub.